number
nucleic
acid
hybrid
amplif
method
use
includ
direct
probe
hybrid
advandx
fish
staphylococcu
aureu
advandx
genprob
group
streptococci
genprob
hybrid
captur
digen
human
papillomaviru
digen
pcr
branchedchain
dna
bdna
bayer
diagnost
transcriptionmedi
amplif
probetec
chlamydia
n
gonorrhoea
becton
dickinson
sampl
volum
encompass
origin
sampl
volum
number
nucleic
acid
sequenc
present
final
amplifi
sampl
portion
transport
condit
dilut
factor
inhibitori
factor
genom
chang
instrument
problem
oper
error
contribut
falseposit
falseneg
test
result
even
close
system
detect
end
prevent
crosscontamin
posit
sampl
process
front
end
exampl
current
fda
restrict
requir
papanicola
smear
first
perform
singl
suspens
cervic
cell
receiv
preserv
request
cytolog
detect
human
papillomaviru
chlamydia
speci
n
gonorrhoea
contribut
common
find
insuffici
sampl
size
remain
infecti
diseas
test
papanicola
sampl
remov
unfortun
unlik
direct
visual
examin
sampl
qualiti
assess
neg
result
assay
includ
comment
qualiti
specimen
although
molecular
test
use
whole
blood
sampl
detect
agent
sepsi
yet
avail
sever
assay
develop
volum
factor
sensit
test
amount
bacteria
blood
obtain
patient
bacteremia
often
cfuml
yet
volum
use
naa
reaction
vial
even
sampl
concentr
way
chanc
microbi
genet
materi
reach
reaction
vial
could
small
result
falseneg
result
sampl
contain
human
neutrophil
sampl
like
harbor
infecti
challeng
concentr
microbi
dna
without
also
ad
overwhelm
amount
human
somat
dna
avail
frontend
method
extract
filtrat
column
magnet
particl
captur
silicabas
system
still
lack
effici
manufactur
spend
energi
backend
technolog
detect
report
frontend
process
urgent
need
ideal
result
develop
creativ
new
method
concentr
cellrich
specimen
purul
fluid
blood
sputum
human
allow
sensit
detect
microbi
nucleic
acid
diagnosi
tubercul
mening
anoth
exampl
problem
inher
amplif
technolog
use
pcr
patient
may
confound
sign
symptom
number
organ
csf
sampl
may
low
convent
test
insensit
andor
slow
direct
acidfast
stain
csf
specimen
sensit
volum
csf
need
adequ
cultur
least
ml
prefer
ml
mycobacterium
tuberculosi
extrem
buoyant
csf
result
waxi
cell
wall
thu
concentr
centrifug
ineffici
smear
acidfast
bacilli
made
sediment
must
layer
examin
hope
detect
rare
tuberculosi
rod
naa
would
seem
answer
sadli
naa
test
display
overal
sensit
rang
specif
rang
determin
metaanalysi
publish
studi
use
homebrew
individu
method
result
laboratori
use
commerci
avail
assay
evalu
separ
overal
sensit
decreas
rang
assay
like
avail
clinician
naa
result
equal
acidfast
bacilli
smear
clinician
must
realiz
unwant
relianc
new
technolog
may
lead
diagnost
error
anoth
highli
favor
technolog
laboratori
diagnosi
infecti
diseas
whether
test
tissu
directli
test
isol
coloni
identif
nucleic
acid
sequenc
also
pitfal
approach
exampl
mani
organ
although
may
antigen
biochem
distinct
virtual
genet
ident
member
bacteroid
fragili
group
exampl
highli
relat
separ
easili
standard
sequenc
method
clinician
realiz
escherichia
coli
shigella
speci
highli
relat
consid
difficulti
related
would
pose
reli
sequenc
identifi
genera
directli
patient
sampl
extent
share
gene
taxonom
versu
phenotyp
share
trait
among
microb
unknown
anoth
issu
vex
clinician
taxonom
confus
caus
genet
investig
rhinosporidium
seeberi
exampl
agent
mass
lesion
sinu
mucou
membran
organ
often
observ
histopatholog
section
never
grown
cultur
resembl
spherul
coccidioid
immiti
howev
long
consid
uncultur
fungu
recent
rrna
sequenc
place
organ
group
protozoan
fish
parasit
constantli
face
new
name
familiar
even
new
organ
may
may
import
familiar
syndrom
moreextens
test
perform
newli
discov
mycoplasma
fermentan
origin
call
mycoplasma
incognitu
implic
gulf
war
syndrom
hiv
infect
later
found
quit
common
human
effect
therapi
result
pcr
genit
sampl
obtain
patient
c
trachomati
remain
posit
week
nucleic
acid
detect
probabl
viabl
know
extent
carriag
uncultur
microbi
normal
microbi
dna
healthi
host
cost
equip
expens
reagent
addit
skill
personnel
need
easi
justifi
exampl
fda
clear
realtim
pcr
test
group
b
streptococc
vaginalrect
colon
labor
widespread
use
test
could
negat
need
perform
cultur
pregnant
women
week
gestat
would
solv
problem
associ
treat
women
present
labor
without
screen
test
result
current
women
receiv
prophylact
penicillin
labor
number
would
decreas
women
pcr
result
posit
group
b
streptococci
labor
treat
problem
howev
current
recommend
alreadi
reduc
incid
earlyonset
neonat
group
b
streptococc
diseas
less
nation
health
object
case
per
live
birth
addit
improv
costeffect
lucil
packard
children
hospit
johnson
center
stanford
univers
medic
center
affili
campu
deliv
babi
annual
perform
pcr
assay
immedi
sampl
receiv
necess
assur
prophylaxi
administ
least
h
deliveri
would
staff
technologist
time
test
perform
take
min
handson
time
test
run
min
technologist
must
perform
continu
sampl
manag
twentyfourseven
staf
day
per
year
would
requir
clinic
laboratori
scientist
labor
overhead
cost
count
cost
instrument
annual
total
yearli
cost
stanford
univers
medic
center
stanford
ca
patient
colon
rate
among
women
labor
result
babi
risk
per
year
prevent
potenti
group
b
streptococc
infect
use
test
cost
per
infect
avoid
would
hard
sell
hospit
administr
focus
bottom
line
potenti
laboratori
staff
labor
save
use
randomaccess
moder
complex
molecular
system
genexpert
mention
may
help
bring
cost
cost
new
technolog
often
ad
onto
exist
test
overal
diagnost
cost
increas
center
medicar
medicaid
servic
reimburs
lag
dramat
behind
use
new
test
northern
california
reimburs
area
laboratori
receiv
pcr
test
bordetella
pertussi
bordetella
parapertussi
although
cost
laboratori
test
sampl
test
alway
perform
one
specimen
time
necessit
test
addit
control
simultan
futur
bleak
cours
new
agent
import
diseas
discov
help
molecular
technolog
among
elucid
recent
tropheryma
whipplei
bartonella
hensela
ehrlichia
chaffeensi
mycoplasma
genitalium
infecti
diseaserel
challeng
readi
solut
new
molecular
tool
etiolog
case
pharyng
unknown
etiolog
case
diarrhea
unknown
etiolog
case
pneumonia
cultiv
organ
subgingiv
crevic
patient
periodont
diseas
mysteri
regard
vex
syndrom
eventu
yield
molecular
technolog
proteom
ie
profil
protein
gener
human
cell
respons
variou
stimuli
includ
compon
product
infecti
agent
infanc
excit
develop
entic
spot
dna
rna
gene
chip
design
homolog
nucleic
acid
sequenc
sampl
repres
nucleic
acid
found
normal
situat
activ
state
transcript
repres
variou
genet
sequenc
uniqu
vast
array
microb
detect
infecti
agent
sampl
treat
break
dna
rna
small
discret
sequenc
ident
sequenc
exist
chip
sampl
nucleic
acid
find
match
bind
emit
electron
signal
humanrespons
chip
use
determin
patient
respons
potenti
toxic
antimicrobi
treatment
advanc
deliveri
patient
lack
enzym
break
toxin
metabol
drug
effect
altern
therapi
use
avoid
danger
advers
effect
anoth
prospect
microarraybas
test
human
leukocyt
respons
variou
infecti
agent
may
use
pinpoint
etiolog
agent
detect
develop
sort
technolog
fast
track
facilit
detect
bioterror
agent
symptomat
phase
diseas
render
widespread
prevent
measur
inadequ
proteom
use
finetun
develop
new
antiinfect
well
one
aspect
microarray
technolog
yet
standard
codifi
monument
problem
data
analysi
entir
new
disciplin
bioinformat
develop
purpos
challeng
interpret
vast
volum
data
point
gener
microarray
studi
acquir
along
technolog
advanc
resolut
requir
collect
extens
effort
summari
futur
potenti
util
incred
numer
other
mention
revolution
infecti
diseas
diagnost
howev
shortcom
technolog
must
recogn
present
danger
includ
failur
support
need
tradit
train
microbiologist
allow
expertis
move
site
distant
patient
care
activ
inappropri
trust
new
technolog
underestim
valu
clinic
diagnosi
base
acumen
experienc
laboratorian
infecti
diseas
practition
